We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.06% | 397.48 | 396.61 | 400.00 | 399.68 | 393.49 | 393.52 | 682,468 | 23:27:33 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Wednesday said it is ending the development of pimodivir, an investigational antiviral treatment for influenza A infection, after disappointing study results.
Janssen said interim analyses of a Phase 3 study in hospitalized patients with influenza A found that pimodivir in combination with the standard of care was very unlikely to show an added benefit compared to standard-of-care treatment alone.
The company said it is halting the trial in hospitalized patients, along with a parallel study in outpatients with influenza A.
Janssen licensed pimodivir in 2014 from Boston drug maker Vertex Pharmaceuticals Inc. in a deal that included an upfront payment of $30 million, along with contingent development and commercial milestone payments.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 02, 2020 09:38 ET (13:38 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
